Match!
Bong Soo Cha
Yonsei University
EndocrinologyType 2 diabetesInsulinDiabetes mellitusMedicine
436Publications
39H-index
6,718Citations
What is this?
Publications 460
Newest
#1H. C. Lee (Yonsei University)H-Index: 4
#2Yongin Cho (IIT: Inha University)
Last. Yong-ho Lee (Yonsei University)H-Index: 24
view all 11 authors...
BACKGROUND There is increasing concern regarding cardiovascular risk in individuals with non-alcoholic fatty liver disease. This study was conducted to evaluate whether hepatic steatosis with or without fibrosis is associated with the progression of carotid atherosclerosis in patients with type 2 diabetes. METHODS From a longitudinal cohort, we enrolled 1120 patients with type 2 diabetes who underwent repeated carotid artery ultrasonography every 1-2 years. Ultrasonographic findings at baseline ...
1 CitationsSource
#2Min Young LeeH-Index: 26
Last. Eun Seok KangH-Index: 33
view all 5 authors...
Source
#2Min Young LeeH-Index: 26
Last. Bong Soo ChaH-Index: 39
view all 6 authors...
Source
#1Sin Gon KimH-Index: 35
#2Kyoung Jin KimH-Index: 1
Last. Ji A Seo (KU: Korea University)H-Index: 34
view all 15 authors...
: We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes mellitus (T2DM) as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were - 0.79% and - 0.86%, respectively; the between-gro...
Source
#1So Ra Kim (Yonsei University)H-Index: 5
#2Sang-Guk Lee (Yonsei University)H-Index: 13
Last. Min-Young Lee (Yonsei University)H-Index: 8
view all 22 authors...
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events in humans with type 2 diabetes (T2D); however, the underlying mechanism remains unclear. Activation of the NLR family, pyrin domain-containing 3 (NLRP3) inflammasome and subsequent interleukin (IL)-1β release induces atherosclerosis and heart failure. Here we show the effect of SGLT2 inhibitor empagliflozin on NLRP3 inflammasome activity. Patients with T2D and high cardiovascular risk receive SGLT2 inhibitor or sulfon...
2 CitationsSource
#1Eugene Han (KMU: Keimyung University)H-Index: 8
#2Ji-Yeon Lee (Yonsei University)H-Index: 10
Last. Yong-ho LeeH-Index: 24
view all 10 authors...
Diabetes is associated with cognitive impairment and greater risk for dementia, but the role of gamma-glutamyltransferase (γ-GT) in dementia has not been elucidated. We determined incident dementia including Alzheimer’s disease and vascular dementia, analyzing data from participants aged 40 years or older in the National Health Insurance Database, collected by the National Health Insurance Service in Korea, from January 2009 to December 2015. During a median follow-up of 7.6 years, 272,657 parti...
Source
#1Eugene HanH-Index: 8
#2Yong-ho LeeH-Index: 24
Last. Bong Soo ChaH-Index: 39
view all 14 authors...
OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) and sarcopenia have a close association with an increased risk of atherosclerotic cardiovascular disease (ASCVD). This study investigated the influence of NAFLD and sarcopenia on ASCVD risk. METHODS: Data from the 2008-2011 Korean National Health and Nutrition Examination Surveys database were analyzed (n = 7,191). The sarcopenia index was calculated using dual-energy x-ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopen...
1 CitationsSource
#1Jaehyun Bae (Yonsei University)H-Index: 1
#2Namki Hong (Yonsei University)H-Index: 9
Last. Yong-ho Lee (Yonsei University)H-Index: 24
view all 6 authors...
Neither lowering of blood lipid levels nor treatment with statins definitively improves renal outcomes. Ezetimibe, a non-statin antilipidemic agent, is known to not only decrease blood lipid levels but also reduce inflammatory response and activate autophagy. We evaluated the effect of adding ezetimibe to a statin on renal outcome compared with statin monotherapy by analyzing longitudinal data of 4537 patients treated with simvastatin 20 mg plus ezetimibe 10 mg (S + E) or simvastatin 20 mg alone...
1 CitationsSource
#1Moon-Kyu Lee (SMC: Samsung Medical Center)H-Index: 30
#1Moon Kyu Lee (SMC: Samsung Medical Center)H-Index: 20
Last. Bong Soo Cha (Yonsei University)H-Index: 39
view all 13 authors...
Abstract Aim MLR-1023, called Tolimidone when evaluated unsuccessfully by Pfizer for gastric ulcer disease, has been repurposed as a novel oral insulin sensitizer with its effects mediated by selective activation of Lyn kinase. We aimed to evaluate the optimal dose, efficacy and safety of MLR-1023 in patients with type 2 diabetes. Methods Type 2 diabetes patients (18–75 years) on diet/exercise therapy were randomized and double-blinded to receive MLR-1023 (100-mg or 200-mg, once-daily [qd] or tw...
Source
#1Eugene HanH-Index: 8
#2Yong-ho LeeH-Index: 24
Last. Bong Soo ChaH-Index: 39
view all 5 authors...
Despite the benefits of pioglitazone in the treatment of non-alcoholic fatty liver disease (NAFLD), many treated patients continue to experience disease progression. We aimed to investigate the additive effect of ipragliflozin on NAFLD in patients with type 2 diabetes treated with metformin and pioglitazone. In this 24-week randomized controlled trial, 44 patients with type 2 diabetes and comorbid NAFLD were either randomized to receive 50 mg/day of ipragliflozin as an add-on treatment (n = 29) ...
1 CitationsSource
12345678910